Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.

ABSTRACT:

Background

There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents. We explored the relationship between body mass index (BMI) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate (PP) in a long-term trial.

Methods

We conducted a post hoc analysis of data from a PP study that included a 33-week open-label transition (TR) and maintenance phase; a variable duration, randomized, double-blind (DB), placebo-controlled phase and a 52-week open-label extension (OLE) phase. Overall, 644 patients received PP continuously from study entry through discontinuation or study completion and were grouped by baseline BMI (kg/m2): un

SUBMITTER: Sliwa JK 

PROVIDER: S-EPMC3941932 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature